Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Techne (TECH)

Bio-Techne Q3 sales rise 4% to $316.2 million; GAAP EPS falls to $0.14

Mixed Impact 4 of 5 earnings Written later

Bio-Techne reported fiscal third-quarter results for the period ended March 31, 2025, with net sales up 4% to $316.2 million and adjusted EPS up to $0.56 from $0.48. GAAP EPS fell to $0.14 from $0.31, as GAAP operating income dropped 42% to $38.7 million, which the company tied to a non-recurring arbitration award and $38.9 million in certain litigation charges. The company also declared an $0.08 quarterly dividend and approved a new $500 million share repurchase program.

Key points

  • Net sales were $316.2 million, up 4% reported and 6% organic.
  • GAAP EPS was $0.14 versus $0.31 a year earlier; adjusted EPS was $0.56 versus $0.48.
  • GAAP operating income fell 42% to $38.7 million, including $38.9 million in certain litigation charges.
  • Dividend of $0.08 per share payable May 30, 2025; new $500 million buyback begins May 8, 2025.

The filing

CompanyBio-Techne (TECH)
Form8-K, current report
Filed with the SECMay 7, 2025, 6:30 AM ET
Accession number0001558370-25-006594

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.